Industry Research Reports
Global NAD+ Intravenous Therapy Market Research Report 2026
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
NAD+ Intravenous Therapy Market Size(US$)
CAGR 2026-2032
8.3%
Market Size,2032
USD 171
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 106 million
Market Forecast in 2032(Value)
US$ 171 million
CAGR
8.3%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
NAD+ IV Therapy is a wellness therapy that involves the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for cellular energy production and metabolic processes. This therapy is believed to boost energy levels, enhance cognitive function, and promote overall cellular repair by increasing NAD+ levels, which naturally decline with age.
1. Evidence-Driven Transition: NAD⁺ IV Therapy Is Shifting from Concept-Based Anti-Aging to Clinically Validated Intervention
The most fundamental long-term trend for NAD⁺ anti-aging intravenous therapy is its transition from a concept-driven wellness service toward an evidence-based clinical intervention. At present, most claimed benefits of NAD⁺ IV—such as anti-fatigue, cognitive enhancement, metabolic optimization, and longevity—are primarily supported by mechanistic studies, animal models, or small observational trials, rather than large-scale randomized controlled trials (RCTs). As regulatory scrutiny increases and medical institutions demand higher scientific rigor, the industry will be forced to generate robust clinical evidence to validate therapeutic outcomes, define clear clinical indications, and demonstrate measurable improvements in objective biomarkers. Over time, NAD⁺ IV is expected to evolve from a loosely defined “anti-aging treatment” into a medically framed intervention with specific use cases, patient stratification, and standardized clinical endpoints.
2. Regulatory Tightening: NAD⁺ IV Therapy Is Moving from a Gray Market into a Strongly Regulated Medical Framework
Another highly certain trend is the progressive tightening of regulatory oversight, which will push NAD⁺ intravenous therapy out of its current semi-gray commercial zone and into a strictly regulated medical framework. In many markets today, NAD⁺ IV is delivered through medical spas, wellness clinics, or functional medicine centers, often without clearly approved indications, standardized drug registration status, or consistent compliance with pharmaceutical regulations. As governments strengthen control over injectable therapies, compounded drugs, and medical advertising, NAD⁺ IV services will increasingly be required to meet formal regulatory standards related to drug sourcing, sterile preparation, clinical justification, physician supervision, and liability management. This regulatory shift will significantly raise entry barriers and is expected to eliminate a large number of low-compliance providers, while favoring hospital systems, licensed clinics, and medically integrated institutions.
3. Safety and Quality Dominance: Sterility, Endotoxin Control, and Supply Chain Integrity Will Become Core Competitive Factors
Safety and pharmaceutical-grade quality control will become the central competitive axis of the NAD⁺ IV industry as it matures. Intravenous administration inherently carries higher systemic risks than oral supplementation, placing stringent demands on sterile manufacturing, endotoxin control, formulation stability, dosage consistency, and cold-chain logistics. Currently, the market exhibits significant heterogeneity in raw material sourcing, preparation standards, and clinical protocols, creating potential safety vulnerabilities. In the future, sustainable operators will be those capable of implementing GMP-level production systems, batch traceability, sterility validation, adverse-event monitoring, and standardized infusion procedures. As a result, NAD⁺ IV therapy will gradually resemble a pharmaceutical medical service rather than a consumer wellness product, with safety compliance itself becoming a major structural barrier to entry.
4. Product Pathway Differentiation: IV Administration Will Become a High-End Niche While Scalable Alternatives Expand
From a product strategy perspective, NAD⁺ IV therapy is structurally constrained from becoming a mass-market solution due to its high operational costs, time-intensive administration, medical dependency, and variability in patient tolerance. As research and commercialization of NAD⁺ precursors and alternative delivery methods continue to advance, market demand will increasingly shift toward more scalable, standardized, and consumer-friendly pathways. In this context, intravenous NAD⁺ will gradually reposition itself as a premium, specialized intervention within functional medicine, longevity clinics, and rehabilitation medicine, while larger market volumes will be captured by non-IV solutions. Long term, NAD⁺ IV is more likely to remain a precision medical tool for specific high-value scenarios rather than a mainstream anti-aging modality.
5. Business Model Evolution: From One-Time Anti-Aging Services to Longitudinal Medical Management Systems
The commercial model of NAD⁺ IV therapy is expected to evolve from transaction-based “anti-aging packages” toward longitudinal medical management systems centered on patient stratification and data feedback. As consumers become more scientifically informed and regulators restrict exaggerated longevity claims, simple service-selling models will lose sustainability. Instead, leading providers will integrate NAD⁺ IV into broader functional medicine frameworks, supported by baseline diagnostics, biomarker tracking, patient segmentation, and outcome monitoring. In this emerging model, NAD⁺ IV is no longer positioned as a standalone product, but as one component within a personalized health optimization ecosystem, where long-term value is generated through continuous medical engagement, data accumulation, and outcome-based service delivery.
This report delivers a comprehensive overview of the global NAD+ Intravenous Therapy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding NAD+ Intravenous Therapy. The NAD+ Intravenous Therapy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global NAD+ Intravenous Therapy market comprehensively. Regional market sizes by Type, by Application, by Injection, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist NAD+ Intravenous Therapy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
- The Wellness Lab
- Conciergemdla
- Azivmedics
- Reset IV
- Thedripclub
- Toronto Functional Medicine Centre
- Mobileivmedics
- Rocky Mountain Ivmedics
- Premiumhealth
- Effect Doctors
- Nadclinic
- Hydrate IV Bar
- LIVV Natural
- BioReset Medical
- IV Boost UK
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- NAD+ Mixed Vitamin Injections
- Pure NAD+ Injection
Segment by Application
- Clinic
- Hospital
- Others
Segment by Category
- Single-use Injection Type
- Recurring Injection Type
- Others
Segment by Division
- Low-dose Type
- Medium-dose Type
- High-dose Type
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Injection, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for NAD+ Intravenous Therapy companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
QYResearch's Strengths
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global NAD+ Intravenous Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 NAD+ Mixed Vitamin Injections
1.2.3 Pure NAD+ Injection
1.3 Market by Injection
1.3.1 Global NAD+ Intravenous Therapy Market Size Growth Rate by Injection: 2021 vs 2025 vs 2032
1.3.2 Single-use Injection Type
1.3.3 Recurring Injection Type
1.3.4 Others
1.4 Market by Dose
1.4.1 Global NAD+ Intravenous Therapy Market Size Growth Rate by Dose: 2021 vs 2025 vs 2032
1.4.2 Low-dose Type
1.4.3 Medium-dose Type
1.4.4 High-dose Type
1.5 Market by Application
1.5.1 Global NAD+ Intravenous Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global NAD+ Intravenous Therapy Market Perspective (2021–2032)
2.2 Global NAD+ Intravenous Therapy Growth Trends by Region
2.2.1 Global NAD+ Intravenous Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 NAD+ Intravenous Therapy Historic Market Size by Region (2021–2026)
2.2.3 NAD+ Intravenous Therapy Forecasted Market Size by Region (2027–2032)
2.3 NAD+ Intravenous Therapy Market Dynamics
2.3.1 NAD+ Intravenous Therapy Industry Trends
2.3.2 NAD+ Intravenous Therapy Market Drivers
2.3.3 NAD+ Intravenous Therapy Market Challenges
2.3.4 NAD+ Intravenous Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top NAD+ Intravenous Therapy Players by Revenue
3.1.1 Global Top NAD+ Intravenous Therapy Players by Revenue (2021–2026)
3.1.2 Global NAD+ Intravenous Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top NAD+ Intravenous Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by NAD+ Intravenous Therapy Revenue
3.4 Global NAD+ Intravenous Therapy Market Concentration Ratio
3.4.1 Global NAD+ Intravenous Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NAD+ Intravenous Therapy Revenue in 2025
3.5 Global Key Players of NAD+ Intravenous Therapy Head Offices and Areas Served
3.6 Global Key Players of NAD+ Intravenous Therapy, Products and Applications
3.7 Global Key Players of NAD+ Intravenous Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 NAD+ Intravenous Therapy Breakdown Data by Type
4.1 Global NAD+ Intravenous Therapy Historic Market Size by Type (2021–2026)
4.2 Global NAD+ Intravenous Therapy Forecasted Market Size by Type (2027–2032)
5 NAD+ Intravenous Therapy Breakdown Data by Application
5.1 Global NAD+ Intravenous Therapy Historic Market Size by Application (2021–2026)
5.2 Global NAD+ Intravenous Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America NAD+ Intravenous Therapy Market Size (2021–2032)
6.2 North America NAD+ Intravenous Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America NAD+ Intravenous Therapy Market Size by Country (2021–2026)
6.4 North America NAD+ Intravenous Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe NAD+ Intravenous Therapy Market Size (2021–2032)
7.2 Europe NAD+ Intravenous Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe NAD+ Intravenous Therapy Market Size by Country (2021–2026)
7.4 Europe NAD+ Intravenous Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific NAD+ Intravenous Therapy Market Size (2021–2032)
8.2 Asia-Pacific NAD+ Intravenous Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific NAD+ Intravenous Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific NAD+ Intravenous Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America NAD+ Intravenous Therapy Market Size (2021–2032)
9.2 Latin America NAD+ Intravenous Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America NAD+ Intravenous Therapy Market Size by Country (2021–2026)
9.4 Latin America NAD+ Intravenous Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NAD+ Intravenous Therapy Market Size (2021–2032)
10.2 Middle East & Africa NAD+ Intravenous Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa NAD+ Intravenous Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa NAD+ Intravenous Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 The Wellness Lab
11.1.1 The Wellness Lab Company Details
11.1.2 The Wellness Lab Business Overview
11.1.3 The Wellness Lab NAD+ Intravenous Therapy Introduction
11.1.4 The Wellness Lab Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.1.5 The Wellness Lab Recent Development
11.2 Conciergemdla
11.2.1 Conciergemdla Company Details
11.2.2 Conciergemdla Business Overview
11.2.3 Conciergemdla NAD+ Intravenous Therapy Introduction
11.2.4 Conciergemdla Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.2.5 Conciergemdla Recent Development
11.3 Azivmedics
11.3.1 Azivmedics Company Details
11.3.2 Azivmedics Business Overview
11.3.3 Azivmedics NAD+ Intravenous Therapy Introduction
11.3.4 Azivmedics Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.3.5 Azivmedics Recent Development
11.4 Reset IV
11.4.1 Reset IV Company Details
11.4.2 Reset IV Business Overview
11.4.3 Reset IV NAD+ Intravenous Therapy Introduction
11.4.4 Reset IV Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.4.5 Reset IV Recent Development
11.5 Thedripclub
11.5.1 Thedripclub Company Details
11.5.2 Thedripclub Business Overview
11.5.3 Thedripclub NAD+ Intravenous Therapy Introduction
11.5.4 Thedripclub Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.5.5 Thedripclub Recent Development
11.6 Toronto Functional Medicine Centre
11.6.1 Toronto Functional Medicine Centre Company Details
11.6.2 Toronto Functional Medicine Centre Business Overview
11.6.3 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Introduction
11.6.4 Toronto Functional Medicine Centre Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.6.5 Toronto Functional Medicine Centre Recent Development
11.7 Mobileivmedics
11.7.1 Mobileivmedics Company Details
11.7.2 Mobileivmedics Business Overview
11.7.3 Mobileivmedics NAD+ Intravenous Therapy Introduction
11.7.4 Mobileivmedics Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.7.5 Mobileivmedics Recent Development
11.8 Rocky Mountain Ivmedics
11.8.1 Rocky Mountain Ivmedics Company Details
11.8.2 Rocky Mountain Ivmedics Business Overview
11.8.3 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Introduction
11.8.4 Rocky Mountain Ivmedics Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.8.5 Rocky Mountain Ivmedics Recent Development
11.9 Premiumhealth
11.9.1 Premiumhealth Company Details
11.9.2 Premiumhealth Business Overview
11.9.3 Premiumhealth NAD+ Intravenous Therapy Introduction
11.9.4 Premiumhealth Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.9.5 Premiumhealth Recent Development
11.10 Effect Doctors
11.10.1 Effect Doctors Company Details
11.10.2 Effect Doctors Business Overview
11.10.3 Effect Doctors NAD+ Intravenous Therapy Introduction
11.10.4 Effect Doctors Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.10.5 Effect Doctors Recent Development
11.11 Nadclinic
11.11.1 Nadclinic Company Details
11.11.2 Nadclinic Business Overview
11.11.3 Nadclinic NAD+ Intravenous Therapy Introduction
11.11.4 Nadclinic Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.11.5 Nadclinic Recent Development
11.12 Hydrate IV Bar
11.12.1 Hydrate IV Bar Company Details
11.12.2 Hydrate IV Bar Business Overview
11.12.3 Hydrate IV Bar NAD+ Intravenous Therapy Introduction
11.12.4 Hydrate IV Bar Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.12.5 Hydrate IV Bar Recent Development
11.13 LIVV Natural
11.13.1 LIVV Natural Company Details
11.13.2 LIVV Natural Business Overview
11.13.3 LIVV Natural NAD+ Intravenous Therapy Introduction
11.13.4 LIVV Natural Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.13.5 LIVV Natural Recent Development
11.14 BioReset Medical
11.14.1 BioReset Medical Company Details
11.14.2 BioReset Medical Business Overview
11.14.3 BioReset Medical NAD+ Intravenous Therapy Introduction
11.14.4 BioReset Medical Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.14.5 BioReset Medical Recent Development
11.15 IV Boost UK
11.15.1 IV Boost UK Company Details
11.15.2 IV Boost UK Business Overview
11.15.3 IV Boost UK NAD+ Intravenous Therapy Introduction
11.15.4 IV Boost UK Revenue in NAD+ Intravenous Therapy Business (2021–2026)
11.15.5 IV Boost UK Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global NAD+ Intravenous Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of NAD+ Mixed Vitamin Injections
Table 3. Key Players of Pure NAD+ Injection
Table 4. Global NAD+ Intravenous Therapy Market Size Growth Rate by Injection (US$ Million): 2021 vs 2025 vs 2032
Table 5. Key Players of Single-use Injection Type
Table 6. Key Players of Recurring Injection Type
Table 7. Key Players of Others
Table 8. Global NAD+ Intravenous Therapy Market Size Growth Rate by Dose (US$ Million): 2021 vs 2025 vs 2032
Table 9. Key Players of Low-dose Type
Table 10. Key Players of Medium-dose Type
Table 11. Key Players of High-dose Type
Table 12. Global NAD+ Intravenous Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 13. Global NAD+ Intravenous Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 14. Global NAD+ Intravenous Therapy Market Size by Region (US$ Million), 2021–2026
Table 15. Global NAD+ Intravenous Therapy Market Share by Region (2021–2026)
Table 16. Global NAD+ Intravenous Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
Table 17. Global NAD+ Intravenous Therapy Market Share by Region (2027–2032)
Table 18. NAD+ Intravenous Therapy Market Trends
Table 19. NAD+ Intravenous Therapy Market Drivers
Table 20. NAD+ Intravenous Therapy Market Challenges
Table 21. NAD+ Intravenous Therapy Market Restraints
Table 22. Global NAD+ Intravenous Therapy Revenue by Players (US$ Million), 2021–2026
Table 23. Global NAD+ Intravenous Therapy Market Share by Players (2021–2026)
Table 24. Global Top NAD+ Intravenous Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on NAD+ Intravenous Therapy Revenue, 2025
Table 25. Ranking of Global Top NAD+ Intravenous Therapy Companies by Revenue (US$ Million) in 2025
Table 26. Global 5 Largest Players Market Share by NAD+ Intravenous Therapy Revenue (CR5 and HHI), 2021–2026
Table 27. Global Key Players of NAD+ Intravenous Therapy, Headquarters and Area Served
Table 28. Global Key Players of NAD+ Intravenous Therapy, Products and Applications
Table 29. Global Key Players of NAD+ Intravenous Therapy, Date of General Availability (GA)
Table 30. Mergers and Acquisitions, Expansion Plans
Table 31. Global NAD+ Intravenous Therapy Market Size by Type (US$ Million), 2021–2026
Table 32. Global NAD+ Intravenous Therapy Revenue Market Share by Type (2021–2026)
Table 33. Global NAD+ Intravenous Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
Table 34. Global NAD+ Intravenous Therapy Revenue Market Share by Type (2027–2032)
Table 35. Global NAD+ Intravenous Therapy Market Size by Application (US$ Million), 2021–2026
Table 36. Global NAD+ Intravenous Therapy Revenue Market Share by Application (2021–2026)
Table 37. Global NAD+ Intravenous Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
Table 38. Global NAD+ Intravenous Therapy Revenue Market Share by Application (2027–2032)
Table 39. North America NAD+ Intravenous Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 40. North America NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2021–2026
Table 41. North America NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2027–2032
Table 42. Europe NAD+ Intravenous Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Europe NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2021–2026
Table 44. Europe NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2027–2032
Table 45. Asia-Pacific NAD+ Intravenous Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 46. Asia-Pacific NAD+ Intravenous Therapy Market Size by Region (US$ Million), 2021–2026
Table 47. Asia-Pacific NAD+ Intravenous Therapy Market Size by Region (US$ Million), 2027–2032
Table 48. Latin America NAD+ Intravenous Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 49. Latin America NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2021–2026
Table 50. Latin America NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2027–2032
Table 51. Middle East & Africa NAD+ Intravenous Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 52. Middle East & Africa NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2021–2026
Table 53. Middle East & Africa NAD+ Intravenous Therapy Market Size by Country (US$ Million), 2027–2032
Table 54. The Wellness Lab Company Details
Table 55. The Wellness Lab Business Overview
Table 56. The Wellness Lab NAD+ Intravenous Therapy Product
Table 57. The Wellness Lab Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 58. The Wellness Lab Recent Development
Table 59. Conciergemdla Company Details
Table 60. Conciergemdla Business Overview
Table 61. Conciergemdla NAD+ Intravenous Therapy Product
Table 62. Conciergemdla Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 63. Conciergemdla Recent Development
Table 64. Azivmedics Company Details
Table 65. Azivmedics Business Overview
Table 66. Azivmedics NAD+ Intravenous Therapy Product
Table 67. Azivmedics Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 68. Azivmedics Recent Development
Table 69. Reset IV Company Details
Table 70. Reset IV Business Overview
Table 71. Reset IV NAD+ Intravenous Therapy Product
Table 72. Reset IV Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 73. Reset IV Recent Development
Table 74. Thedripclub Company Details
Table 75. Thedripclub Business Overview
Table 76. Thedripclub NAD+ Intravenous Therapy Product
Table 77. Thedripclub Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 78. Thedripclub Recent Development
Table 79. Toronto Functional Medicine Centre Company Details
Table 80. Toronto Functional Medicine Centre Business Overview
Table 81. Toronto Functional Medicine Centre NAD+ Intravenous Therapy Product
Table 82. Toronto Functional Medicine Centre Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 83. Toronto Functional Medicine Centre Recent Development
Table 84. Mobileivmedics Company Details
Table 85. Mobileivmedics Business Overview
Table 86. Mobileivmedics NAD+ Intravenous Therapy Product
Table 87. Mobileivmedics Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 88. Mobileivmedics Recent Development
Table 89. Rocky Mountain Ivmedics Company Details
Table 90. Rocky Mountain Ivmedics Business Overview
Table 91. Rocky Mountain Ivmedics NAD+ Intravenous Therapy Product
Table 92. Rocky Mountain Ivmedics Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 93. Rocky Mountain Ivmedics Recent Development
Table 94. Premiumhealth Company Details
Table 95. Premiumhealth Business Overview
Table 96. Premiumhealth NAD+ Intravenous Therapy Product
Table 97. Premiumhealth Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 98. Premiumhealth Recent Development
Table 99. Effect Doctors Company Details
Table 100. Effect Doctors Business Overview
Table 101. Effect Doctors NAD+ Intravenous Therapy Product
Table 102. Effect Doctors Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 103. Effect Doctors Recent Development
Table 104. Nadclinic Company Details
Table 105. Nadclinic Business Overview
Table 106. Nadclinic NAD+ Intravenous Therapy Product
Table 107. Nadclinic Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 108. Nadclinic Recent Development
Table 109. Hydrate IV Bar Company Details
Table 110. Hydrate IV Bar Business Overview
Table 111. Hydrate IV Bar NAD+ Intravenous Therapy Product
Table 112. Hydrate IV Bar Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 113. Hydrate IV Bar Recent Development
Table 114. LIVV Natural Company Details
Table 115. LIVV Natural Business Overview
Table 116. LIVV Natural NAD+ Intravenous Therapy Product
Table 117. LIVV Natural Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 118. LIVV Natural Recent Development
Table 119. BioReset Medical Company Details
Table 120. BioReset Medical Business Overview
Table 121. BioReset Medical NAD+ Intravenous Therapy Product
Table 122. BioReset Medical Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 123. BioReset Medical Recent Development
Table 124. IV Boost UK Company Details
Table 125. IV Boost UK Business Overview
Table 126. IV Boost UK NAD+ Intravenous Therapy Product
Table 127. IV Boost UK Revenue in NAD+ Intravenous Therapy Business (US$ Million), 2021–2026
Table 128. IV Boost UK Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
Table 132. Authors List of This Report
List of Figures
Figure 1. NAD+ Intravenous Therapy Picture
Figure 2. Global NAD+ Intravenous Therapy Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global NAD+ Intravenous Therapy Market Share by Type: 2025 vs 2032
Figure 4. NAD+ Mixed Vitamin Injections Features
Figure 5. Pure NAD+ Injection Features
Figure 6. Global NAD+ Intravenous Therapy Market Size Comparison by Injection (US$ Million), 2021–2032
Figure 7. Single-use Injection Type Features
Figure 8. Recurring Injection Type Features
Figure 9. Others Features
Figure 10. Global NAD+ Intravenous Therapy Market Size Comparison by Dose (US$ Million), 2021–2032
Figure 11. Low-dose Type Features
Figure 12. Medium-dose Type Features
Figure 13. High-dose Type Features
Figure 14. Global NAD+ Intravenous Therapy Market Size by Application (US$ Million), 2021–2032
Figure 15. Global NAD+ Intravenous Therapy Market Share by Application: 2025 vs 2032
Figure 16. Clinic Case Studies
Figure 17. Hospital Case Studies
Figure 18. Others Case Studies
Figure 19. NAD+ Intravenous Therapy Report Years Considered
Figure 20. Global NAD+ Intravenous Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 21. Global NAD+ Intravenous Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global NAD+ Intravenous Therapy Market Share by Region: 2025 vs 2032
Figure 23. Global NAD+ Intravenous Therapy Market Share by Players in 2025
Figure 24. Global NAD+ Intravenous Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. The Top 10 and 5 Players Market Share by NAD+ Intravenous Therapy Revenue in 2025
Figure 26. North America NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. North America NAD+ Intravenous Therapy Market Share by Country (2021–2032)
Figure 28. United States NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Canada NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Europe NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Europe NAD+ Intravenous Therapy Market Share by Country (2021–2032)
Figure 32. Germany NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. France NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. U.K. NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Italy NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Russia NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Ireland NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Asia-Pacific NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Asia-Pacific NAD+ Intravenous Therapy Market Share by Region (2021–2032)
Figure 40. China NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Japan NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. South Korea NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Southeast Asia NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. India NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Australia & New Zealand NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Latin America NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Latin America NAD+ Intravenous Therapy Market Share by Country (2021–2032)
Figure 48. Mexico NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Brazil NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Middle East & Africa NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Middle East & Africa NAD+ Intravenous Therapy Market Share by Country (2021–2032)
Figure 52. Israel NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Saudi Arabia NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. UAE NAD+ Intravenous Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. The Wellness Lab Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 56. Conciergemdla Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 57. Azivmedics Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 58. Reset IV Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 59. Thedripclub Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 60. Toronto Functional Medicine Centre Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 61. Mobileivmedics Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 62. Rocky Mountain Ivmedics Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 63. Premiumhealth Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 64. Effect Doctors Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 65. Nadclinic Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 66. Hydrate IV Bar Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 67. LIVV Natural Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 68. BioReset Medical Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 69. IV Boost UK Revenue Growth Rate in NAD+ Intravenous Therapy Business (2021–2026)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Related Reports
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published Date: 2024-11-11
Pages: 154
USD 4900.00
(Single User License)
Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published Date: 2024-11-11
Pages: 131
USD 4350.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published Date: 2024-11-11
Pages: 100
USD 2900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published Date: 2025-03-13
Pages: 97
USD 2900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 125
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 105
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 158
USD 4900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-31
Pages: 105
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 94
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 133
USD 4900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published: 2024-11-11
Pages: 154
USD 4900.00 (Single User License)Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published: 2024-11-11
Pages: 131
USD 4350.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published: 2024-11-11
Pages: 100
USD 2900.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published: 2025-03-13
Pages: 97
USD 2900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 125
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 105
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 158
USD 4900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-31
Pages: 105
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 94
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 133
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 2900.00
USD 4350.00
USD 5800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
Market Segmentation
QYResearch's Strengths
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
Interest In This Report?
Get A Free Sample
Pre-Order Enquiry
OR
Need a Tailored Report?
Customize this report to your needs.
Customize This Report
Fact Checked
Cite this Research